I would like to know the dose of BCG vaccine for a child of 11 months?

Question

I 'm a student in the college of clinical medicine and would like to know the new doses for BCG.

Answer 1

Dosage of BCG VACCINE SSI
For infants <12 month 0.05 ml of the reconstituted vaccine is recommended

Answer 2

BCG, or bacille Calmette-Guérin, is a vaccine for tuberculosis (TB) disease. BCG is used in many countries with a high prevalence of TB to prevent childhood tuberculous meningitis and miliary disease.

BCG vaccination is not recommended for children infected with HIV
Vaccine Dose, Administration, and Follow-up
BCG vaccination is reserved for persons who have a reaction of <5 mm induration
after skin testing with 5 TU of PPD tuberculin.
The Tice strain of BCG is administered
percutaneously; 0.3 mL of the reconstituted vaccine is usually placed on the skin in the lower deltoid area (i.e., the upper arm) (85 ) and delivered through a multiple-puncture disc.

Infants <30 days of age should receive one half the usual dose, prepared by increasing the amount of diluent added to the lyophilized vaccine. If the indications for vaccination persist, these children should receive a full dose of the vaccine after they are 1 year of age if they have an induration of <5 mm when tested with 5 TU of PPD
tuberculin. Freeze-dried vaccine should be reconstituted, protected from exposure to light, refrigerated when not in use, and used within 8 hours of reconstitution.

Normal reactions to the vaccine are characterized by the formation of a bluish-red pustule within 2–3 weeks after vaccination. After approximately 6 weeks, the pustule
ulcerates, forming a lesion approximately 5 mm in diameter. Draining lesions resulting from vaccination should be kept clean and bandaged. Scabs form and heal usually within 3 months after vaccination. BCG vaccination generally results in a permanent
scar at the puncture site. Accelerated responses to the vaccine might occur in persons infected previously with M. tuberculosis. Hypertrophic scars occur in an estimated
28%–33% of vaccinated persons, and keloid scars occur in approximately 2%–4% (86,87 ). Tuberculin reactivity develops 6–12 weeks after vaccination.

Children. BCG vaccination should only be considered for children who have a negative tuberculin skin test and who are continually exposed, and cannot be separated from, adults who:

1. Are untreated or ineffectively treated for TB disease (if the child cannot be given long-term treatment for infection); or
2. Have TB caused by strains resistant to isoniazid and rifampin.

Contraindications

Immunosuppressed Persons. BCG vaccination should not be given to persons who are immunosuppressed (e.g., persons who are HIV-infected) or who are likely to become immunocompromised (e.g., persons who are candidates for organ transplant).

Tuberculin reactivity resulting from BCG vaccination should be documented. A vaccinated
person should be tuberculin skin tested 3 months after BCG administration, and the test results, in millimeters of induration, should be recorded in the person’s medical records. Vaccinated persons whose skin-test results are negative (i.e., <5 mm of induration) and who are enrolled in ongoing periodic skin-testing programs (e.g., HCWs) should continue to be included in ongoing testing programs if their skin-test results are <5 mm induration.

Those vaccinees who have positive tuberculin skin-test
reactions (³5 mm of induration) after vaccination should not be retested except after exposure to a case of infectious TB; an increase in induration (i.e., ³10 mm increase for
persons <35 years of age and ³15 mm increase for persons ³35 years of age) from a previous to the current skin test may indicate a newly acquired M. tuberculosis infection (see Tuberculin Skin Testing and Interpretation of Results After BCG Vaccination).

BCG is not generally recommended for use in the United States because of the low risk of infection with Mycobacterium tuberculosis, the variable effectiveness of the vaccine against adult pulmonary TB, and the vaccine’s potential interference with tuberculin skin test reactivity. The BCG vaccine should be considered only for very select persons who meet specific criteria and in consultation with a TB expert.

Answer 3

Call a pediatrician in your area ... they can answer that question